Analysts Anticipate Elanco Animal Health Incorporated (NYSE:ELAN) Will Post Quarterly Sales of $1.10 Billion

Wall Street brokerages expect Elanco Animal Health Incorporated (NYSE:ELAN) to post sales of $1.10 billion for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Elanco Animal Health’s earnings, with the lowest sales estimate coming in at $1.09 billion and the highest estimate coming in at $1.12 billion. Elanco Animal Health reported sales of $1.14 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 3.5%. The business is scheduled to announce its next quarterly earnings report on Wednesday, February 23rd.

According to Zacks, analysts expect that Elanco Animal Health will report full year sales of $4.75 billion for the current year, with estimates ranging from $4.75 billion to $4.77 billion. For the next financial year, analysts anticipate that the company will report sales of $4.86 billion, with estimates ranging from $4.79 billion to $4.93 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Elanco Animal Health.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Friday, November 5th. The company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.17 by $0.02. Elanco Animal Health had a positive return on equity of 5.79% and a negative net margin of 14.56%. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the previous year, the company earned $0.13 EPS. The company’s quarterly revenue was up 27.1% on a year-over-year basis.

Several analysts have recently issued reports on ELAN shares. Credit Suisse Group assumed coverage on shares of Elanco Animal Health in a research note on Thursday, August 5th. They set an “outperform” rating and a $38.00 price objective for the company. Morgan Stanley started coverage on shares of Elanco Animal Health in a research report on Thursday, November 18th. They issued an “overweight” rating and a $40.00 price objective for the company. Stifel Nicolaus lowered shares of Elanco Animal Health from a “buy” rating to a “hold” rating and cut their target price for the company from $37.00 to $34.00 in a research note on Thursday, October 28th. Finally, Zacks Investment Research upgraded shares of Elanco Animal Health from a “sell” rating to a “hold” rating in a research note on Tuesday, November 9th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Buy” and a consensus price target of $37.25.

ELAN traded down $1.28 during trading on Friday, hitting $30.79. The company’s stock had a trading volume of 3,431,800 shares, compared to its average volume of 3,703,289. The firm’s 50 day moving average price is $32.59 and its 200-day moving average price is $33.65. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.32 and a quick ratio of 1.30. The stock has a market cap of $14.57 billion, a PE ratio of -21.68, a PEG ratio of 0.64 and a beta of 0.82. Elanco Animal Health has a twelve month low of $27.33 and a twelve month high of $37.49.

In other news, major shareholder Elanco Animal Health Inc purchased 45,508,938 shares of the company’s stock in a transaction on Friday, August 27th. The shares were purchased at an average cost of $9.25 per share, with a total value of $420,957,676.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director R David Hoover purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 15th. The stock was acquired at an average price of $31.79 per share, for a total transaction of $158,950.00. The disclosure for this purchase can be found here. 6.11% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Tompkins Financial Corp bought a new position in Elanco Animal Health in the 1st quarter valued at approximately $27,000. Captrust Financial Advisors acquired a new stake in shares of Elanco Animal Health during the 1st quarter worth approximately $28,000. Herold Advisors Inc. acquired a new stake in shares of Elanco Animal Health during the 3rd quarter worth approximately $31,000. Clearstead Advisors LLC acquired a new stake in Elanco Animal Health in the 3rd quarter valued at $31,000. Finally, Berman Capital Advisors LLC grew its position in Elanco Animal Health by 155.2% in the 2nd quarter. Berman Capital Advisors LLC now owns 929 shares of the company’s stock valued at $32,000 after purchasing an additional 565 shares during the period. Institutional investors own 98.46% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health, Inc engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.

Read More: Correction

Get a free copy of the Zacks research report on Elanco Animal Health (ELAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.